- Home
- Europe Viscosupplementation Market
Europe Viscosupplementation Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-564 | No of pages: 270 | Format:
Europe viscosupplementation market is projected to register a substantial CAGR of 7.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2022 to 2029.
Market Segmentation:
Europe Viscosupplementation Market, By Source (animal origin and non-animal origin), Age Group (geriatric and adults), Injection (single injection, three injections, and five injections), Molecular Weight (intermediate molecular weight, low molecular weight, and high molecular weight), End User (hospital, orthopedic clinics, ambulatory care centers, and others), Distribution Channel (direct tender and retail sales), Country(Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Poland, Austria, Hungary, Lithuania, Norway, Ireland, and the rest of Europe) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the Europe viscosupplementation market are:
Rising geriatric population
Increasing risk of osteoporosis and osteoarthritis
Market Segmentation:
Europe viscosupplementation market is categorized into six notable segments: source, age group, molecular weight, injection, end user, and distribution channel.
On the basis of source, the Europe viscosupplementation market is segmented into the animal origin and non-animal origin
On the basis of molecular weight, the Europe viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight
On the basis of injection, the Europe viscosupplementation market is segmented into single injection, three injections, and five injections
On the basis of age group, the Europe viscosupplementation market is segmented into geriatric and adults
On the basis of end-user, the Europe viscosupplementation market is segmented into hospitals, orthopedic clinics, ambulatory care centers, and others
On the basis of distribution channel, the Europe viscosupplementation market is segmented into direct tender and retail sales
Market Players:
The key market players Operatin in the Europe viscosupplementation market are listed below:
APTISSEN
Johnson & Johnson Services, Inc.
LG Chem.
Viatris Inc.
IBSA Institut Biochimique SA
Ortobrand International
TRB CHEMEDICA SA
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 60
1.1 OBJECTIVES OF THE STUDY 60
1.2 MARKET DEFINITION 60
1.3 OVERVIEW OF EUROPE VISCOSUPPLEMENTATION MARKET 60
1.4 CURRENCY AND PRICING 62
1.5 LIMITATIONS 62
1.6 MARKETS COVERED 63
2 MARKET SEGMENTATION 66
2.1 MARKETS COVERED 66
2.2 GEOGRAPHICAL SCOPE 67
2.3 YEARS CONSIDERED FOR THE STUDY 68
2.4 DBMR TRIPOD DATA VALIDATION MODEL 69
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 72
2.6 MULTIVARIATE MODELLING 73
2.7 MARKET APPLICATION COVERAGE GRID 74
2.8 SOURCE LIFELINE CURVE 75
2.9 DBMR MARKET POSITION GRID 76
2.10 VENDOR SHARE ANALYSIS 77
2.11 SECONDARY SOURCES 78
2.12 ASSUMPTIONS 78
3 EXECUTIVE SUMMARY 79
4 PREMIUM INSIGHT 83
4.1 PESTEL 84
4.2 PORTER'S FIVE FORCES MODEL 85
5 EPIDEMIOLOGY 86
6 INDUSTRIAL INSIGHTS 87
7 PIPELINE ANALYSIS FOR EUROPE VISCOSUPPLEMENTATION MARKET 89
8 EUROPE VISCOSUPPLEMENTATION MARKET: REGULATIONS 90
9 MARKET OVERVIEW 93
9.1 DRIVERS 95
9.1.1 RISING GERIATRIC POPULATION 95
9.1.2 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS 95
9.1.3 TECHNOLOGICAL ADVANCEMENT IN VISCOSUPPLEMENTATION 96
9.1.4 LOW PRODUCTION COST OF VISCOSUPPLEMENTATION PRODUCTS 96
9.2 RESTRAINTS 96
9.2.1 LACK OF TECHNICAL EXPERTISE 96
9.2.2 PRODUCT RECALL PROCEDURES 97
9.2.3 LIMITED APPLICATIONS OF VISCOSUPPLEMENTATION 97
9.3 OPPORTUNITIES 97
9.3.1 SAFETY AND EFFECTIVENESS OF INTRA-ARTICULAR HYALURONIC ACID (IAHA) 97
9.3.2 RISING HEALTHCARE INFRASTRUCTURE 98
9.3.3 INCREASE IN DEMAND FOR MINIMALLY INVASIVE PROCEDURES 98
9.3.4 INCREASING NUMBER OF JOINT REPLACEMENTS AND SPORTS ACCIDENT 99
9.4 CHALLENGES 99
9.4.1 STRINGENT GOVERNMENT POLICIES FOR THE USE OF VISCOSUPPLEMENTATION 99
9.4.2 SIDE-EFFECTS OF VISCOSUPPLEMENTATION 100
10 EUROPE VISCOSUPPLEMENTATION MARKET, BY SOURCE 101
10.1 OVERVIEW 102
10.2 NON-ANIMAL ORIGIN 104
10.2.1 ORTHOVISC 106
10.2.2 EUFLEXXA 106
10.2.3 MONOVISC 106
10.2.4 DUROLANE 106
10.2.5 GEL-ONE 107
10.2.6 SUPARTZ 107
10.2.7 GELSYN-3 107
10.2.8 CINGAL 107
10.2.9 SULPLASYN 107
10.2.10 VISCOSEAL 107
10.2.11 OSTEONIL 107
10.2.12 OTHERS 107
10.3 ANIMAL ORIGIN 107
10.3.1 HYLAN G-F 20 108
10.3.2 SYNVIC ONE 109
10.3.3 SYNVIC 109
10.3.4 OTHERS 109
10.3.5 HYALURONANS 109
10.3.6 HYALGAN 110
10.3.7 OTHERS 110
11 EUROPE VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT 111
11.1 OVERVIEW 112
11.2 INTERMEDIATE MOLECULAR WEIGHT 114
11.2.1 ORTHOVISC 115
11.2.2 EUFLEXXA 115
11.2.3 MONOVISC 116
11.2.4 DUROLANE 116
11.2.5 VISCOSEAL 116
11.2.6 OSTEONIL 116
11.2.7 OTHERS 116
11.3 LOW MOLECULAR WEIGHT 116
11.3.1 HYLAGAN 117
11.3.2 SUPARTZ 117
11.3.3 GELSYN-3 117
11.3.4 CINGAL 117
11.3.5 SULPLASYN 118
11.3.6 OTHERS 118
11.4 HIGH MOLECULAR WEIGHT 118
11.4.1 SYNVIC ONE 119
11.4.2 SYNVIC 119
11.4.3 OTHERS 119
12 EUROPE VISCOSUPPLEMENTATION MARKET, BY INJECTION 120
12.1 OVERVIEW 121
12.2 SINGLE INJECTION 123
12.3 THREE INJECTION 124
12.4 FIVE INJECTION 125
13 EUROPE VISCOSUPPLEMENTATION MARKET, BY AGE GROUP 126
13.1 OVERVIEW 127
13.2 ADULTS 129
13.3 GERIATRIC 130
14 EUROPE VISCOSUPPLEMENTATION MARKET, BY END USER 131
14.1 OVERVIEW 132
14.2 HOSPITALS 134
14.3 ORTHOPEDIC CLINICS 135
14.4 AMBULATORY CARE CENTERS 136
14.5 OTHERS 137
15 EUROPE VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL 138
15.1 OVERVIEW 139
15.2 RETAIL SALES 141
15.3 DIRECT TENDER 142
16 EUROPE VISCOSUPPLEMENTATION MARKET, BY REGION 143
16.1 EUROPE 144
16.1.1 GERMANY 153
16.1.2 FRANCE 158
16.1.3 U.K. 163
16.1.4 ITALY 168
16.1.5 RUSSIA 173
16.1.6 SPAIN 177
16.1.7 TURKEY 182
16.1.8 NETHERLANDS 187
16.1.9 SWITZERLAND 192
16.1.10 POLAND 197
16.1.11 HUNGARY 203
16.1.12 AUSTRIA 209
16.1.13 NORWAY 214
16.1.14 IRELAND 219
16.1.15 LITHUANIA 224
16.1.16 REST OF EUROPE 229
17 EUROPE VISCOSUPPLEMENTATION MARKET: COMPANY LANDSCAPE 230
17.1 COMPANY SHARE ANALYSIS: EUROPE 230
18 SWOT ANALYSIS 231
19 COMPANY PROFILE 232
19.1 JOHNSON & JOHNSON SERVICES, INC. 232
19.1.1 COMPANY SNAPSHOT 232
19.1.2 REVENUE ANALYSIS 232
19.1.3 COMPANY SHARE ANALYSIS 233
19.1.4 PRODUCT PORTFOLIO 233
19.1.5 RECENT DEVELOPMENTS 233
19.2 BIOVENTUS 234
19.2.1 COMPANY SNAPSHOT 234
19.2.2 REVENUE ANALYSIS 234
19.2.3 COMPANY SHARE ANALYSIS 235
19.2.4 PRODUCT PORTFOLIO 235
19.2.5 RECENT DEVELOPMENTS 236
19.3 FERRING B.V. 237
19.3.1 COMPANY SNAPSHOT 237
19.3.2 COMPANY SHARE ANALYSIS 237
19.3.3 PRODUCT PORTFOLIO 237
19.3.4 RECENT DEVELOPMENT 237
19.4 SANOFI-AVENTIS U.S. LLC 238
19.4.1 COMPANY SNAPSHOT 238
19.4.2 REVENUE ANALYSIS 238
19.4.3 COMPANY SHARE ANALYSIS 239
19.4.4 PRODUCT PORTFOLIO 239
19.4.5 RECENT DEVELOPMENTS 239
19.5 ZIMMER BIOMET 240
19.5.1 COMPANY SNAPSHOT 240
19.5.2 REVENUE ANALYSIS 240
19.5.3 COMPANY SHARE ANALYSIS 241
19.5.4 PRODUCT PORTFOLIO 241
19.5.5 RECENT DEVELOPMENTS 242
19.6 SEIKAGAKU CORPORATION 243
19.6.1 COMPANY SNAPSHOT 243
19.6.2 REVENUE ANALYSIS 243
19.6.3 PRODUCT PORTFOLIO 244
19.6.4 RECENT DEVELOPMENTS 244
19.7 ANIKA THERAPEUTICS, INC. 245
19.7.1 COMPANY SNAPSHOT 245
19.7.2 REVENUE ANALYSIS 245
19.7.3 PRODUCT PORTFOLIO 246
19.7.4 RECENT DEVELOPMENTS 246
19.8 FIDIA FARMACEUTICI S.P.A 247
19.8.1 COMPANY SNAPSHOT 247
19.8.2 REVENUE ANALYSIS 247
19.8.3 PRODUCT PORTFOLIO 247
19.8.4 RECENT DEVELOPMENT 248
19.9 APTISSEN 249
19.9.1 COMPANY SNAPSHOT 249
19.9.2 PRODUCT PORTFOLIO 249
19.9.3 RECENT DEVELOPMENT 249
19.10 IBSA INSTITUT BIOCHIMIQUE SA 250
19.10.1 COMPANY SNAPSHOT 250
19.10.2 PRODUCT PORTFOLIO 250
19.10.3 RECENT DEVELOPMENT 250
19.11 LG CHEM. 251
19.11.1 COMPANY SNAPSHOT 251
19.11.2 REVENUE ANALYSIS 251
19.11.3 PRODUCT PORTFOLIO 252
19.11.4 RECENT DEVELOPMENTS 252
19.12 LIFECORE (A SUBSIDIARY OF LANDEC CORPORATION) 253
19.12.1 COMPANY SNAPSHOT 253
19.12.2 REVENUE ANALYSIS 253
19.12.3 PRODUCT PORTFOLIO 254
19.12.4 RECENT DEVELOPMENTS 254
19.13 ORTHOGENRX, INC. (A SUBSIDIARY OF AVNS) 255
19.13.1 COMPANY SNAPSHOT 255
19.13.2 REVENUE ANALYSIS 255
19.13.3 PRODUCT PORTFOLIO 255
19.13.4 RECENT DEVELOPMENTS 256
19.14 ORTOBRAND INTERNATIONAL 257
19.14.1 COMPANY SNAPSHOT 257
19.14.2 PRODUCT PORTFOLIO 257
19.14.3 RECENT DEVELOPMENT 257
19.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. 258
19.15.1 COMPANY SNAPSHOT 258
19.15.2 REVENUE ANALYSIS 258
19.15.3 PRODUCT PORTFOLIO 259
19.15.4 RECENT DEVELOPMENTS 259
19.16 TRB CHEMEDICA SA 260
19.16.1 COMPANY SNAPSHOT 260
19.16.2 PRODUCT PORTFOLIO 260
19.16.3 RECENT DEVELOPMENTS 261
19.17 VIATRIS INC. 262
19.17.1 COMPANY SNAPSHOT 262
19.17.2 REVENUE ANALYSIS 262
19.17.3 PRODUCT PORTFOLIO 263
19.17.4 RECENT DEVELOPMENTS 263
19.18 VIRCHOW BIOTECH 264
19.18.1 COMPANY SNAPSHOT 264
19.18.2 PRODUCT PORTFOLIO 264
19.18.3 RECENT DEVELOPMENT 264
19.19 ZUVENTUS HEALTHCARE LTD. (A SUBSIDIARY OF EMCURE PHARMACEUTICALS) 265
19.19.1 COMPANY SNAPSHOT 265
19.19.2 REVENUE ANALYSIS 265
19.19.3 PRODUCT PORTFOLIO 266
19.19.4 RECENT DEVELOPMENT 266
20 QUESTIONNAIRE 267
21 RELATED REPORTS 270
Segmentation
Short Description
Europe Viscosupplementation Market, By Source (animal origin and non-animal origin), Age Group (geriatric and adults), Injection (single injection, three injections, and five injections), Molecular Weight (intermediate molecular weight, low molecular weight, and high molecular weight), End User (hospital, orthopedic clinics, ambulatory care centers, and others), Distribution Channel (direct tender and retail sales) Country(Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Poland, Austria, Hungary, Lithuania, Norway, Ireland, and the rest of Europe) Industry Trends and Forecast to 2029.
Market Definition:
The development of the therapeutic paradigm viscosupplementation for long-lasting pain relief in human and animal joints with osteoarthritis or traumatic arthritis was based on the finding that in arthritic conditions, the average molecular weight and concentration of hyaluronan decreased. Consequently, the elastoviscous properties of the synovial fluid are substantially reduced. Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times greater concentration than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan used today for therapeutic purposes, the rheological properties (viscosity and elasticity) are low. Therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions. It has comparable rheological properties to the fluid found in young, healthy individuals. The clinical benefit of viscosupplementation is long-lasting pain relief in arthritic joints.
Furthermore, the increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market.
Market Segmentation:
Europe viscosupplementation market is categorized into six notable segments which are the source, age group, molecular weight, injection, end user, and distribution channel.
On the basis of source, the Europe viscosupplementation market is segmented into animal origin and non-animal origin. Animal origin is further segmented into by type, hyaluronans, by brands, hylan G-F 20, by brand, Synvisc, and Synvisc one. Hyaluronans, by brands, are further segmented into hyalgan. Non-animal origin is segmented into SULPLASYN, GEL ONE, ORTHOVISC, MONOVISC, OSTEONIL, VISCOSEAL, EUFLEXXA, DUROLANE, SUPARTZ, GELSYN-3, and CINGEAL. In 2022, the non-animal origin segment is expected to dominate the Europe viscosupplementation market due to the increased density of hyaluronic acid (HA). Also, it displays high resistance to intraarticular degradation
On the basis of age group, the Europe viscosupplementation market is segmented into geriatric and adults. In 2022, the geriatric segment is expected to dominate the Europe viscosupplementation market due to an increase in the population
On the basis of injection, the Europe viscosupplementation market is segmented into single injection, three injections, and five injections. In 2022, the single injection segment is expected to dominate the Europe viscosupplementation market due to high responsiveness levels to single-injection treatment and a more prominent inclination toward the administration of osteoarthritis
On the basis of molecular weight, the Europe viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight. In 2022, the intermediate molecular weight segment is expected to dominate the Europe viscosupplementation market due to the molecular weight of hyaluronic acid having a major influence on its efficacy and safety for viscosupplementation in hip osteoarthritis
On the basis of end-user, the Europe viscosupplementation market is segmented into hospital, orthopedic clinics, ambulatory care centers, and others. In 2022, the hospital segment is expected to dominate the Europe viscosupplementation market due to rising preferences among customers
On the basis of distribution channel, the Europe viscosupplementation market is segmented into direct tender and retail sales. In 2022, the direct tender segment is expected to dominate the Europe viscosupplementation market as it is most commonly used by research labs, pharmaceutical shops, and hospitals
Market Players
The key market players for Europe viscosupplementation market are listed below:
Zimmer Biomet
OrthogenRx, Inc. (a subsidiary of AVNS)
APTISSEN
Johnson & Johnson Services, Inc.
LG Chem.
Viatris Inc.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.